TOYOPEARL® MX-Trp-650M Mixed-Mode Resin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

TOYOPEARL® MX-Trp-650M Mixed-Mode Resin


TOYOPEARL® MX-Trp-650M is a new multimodal cation exchange resin with unique selectivity and high recovery. It provides high protein binding capacities and tolerates high conductivity feedstocks.

TOYOPEARL® MX-Trp-650M is based on a rigid methacrylic polymer matrix, which provides excellent pressure/flow properties and allows high flow rates at large scale. Its ligand, the amino acid tryptophan, provides ionic and hydrophobic interactions. TOYOPEARL® MX-Trp-650M combines the selectivity options of mixed-mode chromatography with the binding capacity of modern ion exchange resins. This new mixed-mode resin is well-suited for intermediate and polishing steps, such as aggregate removal in antibody purification, and for the purification of targets that are difficult to purify using common purification platforms.

For more information visit the website www.tosohbioscience.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here